Literature DB >> 7827876

Iodized oil in the treatment of hepatocellular carcinoma.

S Bhattacharya1, J R Novell, M C Winslet, K E Hobbs.   

Abstract

When injected into the hepatic artery the contrast agent Lipiodol (iodized poppy seed oil) is selectively retained by hepatocellular carcinoma (HCC) for a prolonged period of time. Liver computed tomography (CT) performed after Lipiodol angiography is more sensitive than ordinary CT at imaging HCC. Arterial administration of cytotoxic drugs and radioisotopes conjugated to Lipiodol has been shown to be reasonably safe in patients with irresectable HCC. These therapies, often combined with embolization, provide effective palliation, better tumour response and improved survival compared with other available treatments. Their use as a preoperative adjunct to surgical resection of HCC is controversial.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7827876     DOI: 10.1002/bjs.1800811105

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  16 in total

Review 1.  Transarterial approaches to primary and secondary hepatic malignancies.

Authors:  Ali Habib; Kush Desai; Ryan Hickey; Bartley Thornburg; Robert Lewandowski; Riad Salem
Journal:  Nat Rev Clin Oncol       Date:  2015-05-19       Impact factor: 66.675

Review 2.  Rationale of transcatheter intra-arterial therapies of hepatic cancers.

Authors:  Ryan M Hickey; Robert J Lewandowski; Riad Salem
Journal:  Hepat Oncol       Date:  2014-09-09

3.  Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement.

Authors:  Roderich E Schwarz; Ghassan K Abou-Alfa; Jeffrey F Geschwind; Sunil Krishnan; Riad Salem; Alan P Venook
Journal:  HPB (Oxford)       Date:  2010-06       Impact factor: 3.647

Review 4.  Transcatheter intraarterial therapies: rationale and overview.

Authors:  Robert J Lewandowski; Jean-Francois Geschwind; Eleni Liapi; Riad Salem
Journal:  Radiology       Date:  2011-06       Impact factor: 11.105

Review 5.  Ablation plus Transarterial Embolic Therapy for Hepatocellular Carcinoma Larger than 3 cm: Science, Evidence, and Future Directions.

Authors:  Andrew R Lewis; Carlos A Padula; J Mark McKinney; Beau B Toskich
Journal:  Semin Intervent Radiol       Date:  2019-10-31       Impact factor: 1.513

Review 6.  Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective.

Authors:  Ronnie Tung-Ping Poon; Sheung-Tat Fan; Flora Hau-Fung Tsang; John Wong
Journal:  Ann Surg       Date:  2002-04       Impact factor: 12.969

Review 7.  Transcatheter arterial chemoembolization for liver cancer: is it time to distinguish conventional from drug-eluting chemoembolization?

Authors:  Eleni Liapi; Jean-Francois H Geschwind
Journal:  Cardiovasc Intervent Radiol       Date:  2010-11-12       Impact factor: 2.740

8.  Systematic Review and Pharmacokinetic Meta-analysis of Doxorubicin Exposure in Transcatheter Arterial Chemoembolization and Doxorubicin-Eluted Beads Chemoembolization for Treatment of Unresectable Hepatocellular Carcinoma.

Authors:  Mohammadreza Zarisfi; Arta Kasaeian; Anna Wen; Eleni Liapi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2022-05-11       Impact factor: 2.441

9.  Local drug delivery system using ceramics: vacuum method for impregnating a chemotherapeutic agent into a porous hydroxyapatite block.

Authors:  M Itokazu; M Esaki; K Yamamoto; T Tanemori; T Kasai
Journal:  J Mater Sci Mater Med       Date:  1999-04       Impact factor: 3.896

10.  Tumor uptake of hollow gold nanospheres after intravenous and intra-arterial injection: PET/CT study in a rabbit VX2 liver cancer model.

Authors:  Mei Tian; Wei Lu; Rui Zhang; Chiyi Xiong; Joe Ensor; Javier Nazario; James Jackson; Colette Shaw; Katherine A Dixon; Jennifer Miller; Kenneth Wright; Chun Li; Sanjay Gupta
Journal:  Mol Imaging Biol       Date:  2013-10       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.